Announcements
- Cytek® Biosciences Names William McCombe Chief Financial Officer
- Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
- Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
- Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry
- Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare Conference
More ▼
Key statistics
On Friday, Cytek Biosciences Inc (8EQ:DEU) closed at 5.45, 73.57% above the 52 week low of 3.14 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.60 |
---|---|
High | 5.60 |
Low | 5.35 |
Bid | 5.45 |
Offer | 5.50 |
Previous close | 5.55 |
Average volume | 51.00 |
---|---|
Shares outstanding | 130.82m |
Free float | 119.43m |
P/E (TTM) | -- |
Market cap | 779.71m USD |
EPS (TTM) | -0.0887 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 19:08 BST.
More ▼